Clinical Trials

The Cancer Center of Central Connecticut conducts a number of clinical trials in an effort to find more effective cancer treatments.

New therapies developed in clinical trials have improved cancer care for many diseases. Clinical trials today will help our patients by providing them access to investigational drugs. Scientific knowledge gained through these clinical trials will improve our cancer treatments in the future.Below is a list of Clinical Trials that the Cancer Center of Central Connecticut is currently conducting:

Lung Cancer Clinical Trials

  • Bristol Meyers-Squibb CA209-9LA
    A study of Nivolumab plus Ipilimumab in combination with chemotherapy vs. chemotherpy alone as first line therapy in Stage IV Non-Small Cell Lung Cancer (NSLC).
  • Bristol-Myers Squibb CA209816A randomized, open-label, Phase 3 trial of Nivolumab and Ipilimumab versus Platinum-Doublet chemotherapy in early stage NSCLC (stage IB-IIIA)
  • Beyondspring BPI 2358-103 A randomized, single-blinded, Phase 3 study of second or third line chemotherapy with Docetaxel + Placebo in patients with advanced non-small cell lung cancer with at least one measureable lung lesion (DUBLIN-3).  Must have prior platinum therapy

Hematologic Malignancies/Lymphoma Clincial Trials

  • Bristol-Myers Squibb CA209812
    Randomized, open-label, Phase 3 trial of Nivolumab plus Brentuximab vedotin versus Brentuximab vedotin alone in participants with Replased Refractory or ineligible for Autologous Stem Cell Transplant (ASCT) Advanced Stage Classical Hodgkin Lymphoma (Checkmate 812: CHECKpoint pathway and Nivolumab clinical trial evaluation 812)
  • INCB 50465-203 A Phase 2, multicenter, open-label, randomized study comparing INCB050465, a PI3K8 inhibitor , to Idelalisib in relapsed or Refractory Follicular Lymphoma (CITADEL-203)
  • Morphosys A Phase II/III randomized, multicentre study of MOR00208 with Bendamustine versus Rituxumab with Bendumustine in patients with relapsed or refractory Difuse large B Cell lymphoma (RR DLBCL) who are not eligible for High Dose chemotherapy( HDC) and autologous Stem-Cell Transportation (ASCT - B-Mind.

Iron Deficiency Anemia

  • IDA-03   A phase III, randomized, open-label, comparative safety and efficacy trial of intraveneous iron isomaltoside (Monofor) and iron sucrose in subjects with iron deficiency anemia who are intolerant or unresponsive to oral iron therapy or whom the hemoglobin measurement in Investigator's opinion were sufficiently low as to require rapid repletion of iron stores to minimize the risk of receiving a blood transfusion.
  • CKD-04   A phase III, randomized, open label comparative safety and efficacy trial of interveneous iron isomaltoside (Monofer) and iron sucrose in subjects with iron deficiency anemia and nondialysis dependent kidney disease.

MDS

  • 04-30   A phase III, international, randomized, controlled study of Rigosertib versus physicians choice of treatment in patients with Myelodysplastic Syndrome after failure of a hypomethylating agent.  (Opening May 19, 2017) 

Renal Cell

  • EISAI E7080-G0000-218 a randomized, double-blinded, Phase 2 trial to assess safety and efficacy of Lenvatinib at two different starting doses (18 mg vs. 14 mg QD) in combination with Everolimus (5 mg QD) in Renal Cell Carcinoma following one prior VEGF-targeted treatment. 

Head and Neck

  • A randomized, double-blinded, placebo-controlled Phase 3 study of Nivolumab or Nivolumab plus Cisplatin in combination with radiotherapy in participants with Cisplatin ineligible and Cisplatin eligible locally advanced squamous cell carconoma of the head and neck.